PCRX — PACIRA BIOSCIENCES, INC. (Healthcare >> Drug Manufacturers - Specialty & Generic)
PCRX FAQ
What is PCRX's P/E ratio?
PACIRA BIOSCIENCES, INC. (PCRX) currently trades at a P/E ratio of 89.65.
What is PCRX's ROE?
PACIRA BIOSCIENCES, INC. reports a Return on Equity (ROE) of 0.79%.
What is PCRX's dividend yield?
PACIRA BIOSCIENCES, INC. offers a dividend yield of 0.00%.
What is PCRX's Deepscope Quality Score?
Deepscope rates PCRX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PCRX?
Deepscope's AI Timing Score for PCRX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PCRX belong to?
PACIRA BIOSCIENCES, INC. is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 22.86
Price
0.11
(0.48%)
Day Change
|
|
|---|
PCRX Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
3069
|
| Magic Formula Rank by ROE |
3069
|
| Magic Formula Rank by ROIC |
2962
|
| Price | 22.86 |
| PBV / Sector |
1.37 / 2.63
GOOD
|
| Earning Per Share | 0.13 |
| PE / Sector |
89.65 / 23.62
|
| PEG or PE/Growth / Sector |
-0.80 / 0.12
|
| Average 1M Daily Value |
9.97 M
|
| Average 1W Daily Value |
7.70 M
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
50% |
| Khả năng kiếm lợi nhuận |
|
56% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-09 09:39:47 |
| Symbol | PCRX |
| Name | PACIRA BIOSCIENCES, INC. |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 39.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 895.17 / 9,799.42 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
Phone: 650 242 8052
Website: https://www.pacira.com
Employees: 825
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google